Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of remibrutinib in generalized myasthenia gravis with open-label extension
CTR20252589Phase 3Terminated
- Sponsor
- 不适用/ 诺华（中国）生物医学研究有限公司
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of remibrutinib in myasthenia gravis (MG), sponsored by 不适用/ 诺华（中国）生物医学研究有限公司. Started Sep 2025; status: terminated.
02
Drugs
remibrutinib
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on CTR20252589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252589.